- Home
- EVAX vs KZIA Comparison
EVAX vs KZIA Comparison
Compare EVAX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- KZIA
- Stock Information
- Founded
- EVAX 2008
- KZIA 1994
- Country
- EVAX Denmark
- KZIA Australia
- Employees
- EVAX N/A
- KZIA N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- KZIA Health Care
- Exchange
- EVAX Nasdaq
- KZIA Nasdaq
- Market Cap
- EVAX 8.7M
- KZIA 7.8M
- IPO Year
- EVAX 2021
- KZIA 1999
- Fundamental
- Price
- EVAX $2.41
- KZIA $1.32
- Analyst Decision
- EVAX Strong Buy
- KZIA Strong Buy
- Analyst Count
- EVAX 2
- KZIA 1
- Target Price
- EVAX $11.00
- KZIA $20.00
- AVG Volume (30 Days)
- EVAX 250.1K
- KZIA 106.9K
- Earning Date
- EVAX 10-31-2024
- KZIA 11-15-2024
- Dividend Yield
- EVAX N/A
- KZIA N/A
- EPS Growth
- EVAX N/A
- KZIA N/A
- EPS
- EVAX N/A
- KZIA N/A
- Revenue
- EVAX $3,295,000.00
- KZIA $1,655,324.00
- Revenue This Year
- EVAX $4,845.21
- KZIA $806.89
- Revenue Next Year
- EVAX $30.30
- KZIA N/A
- P/E Ratio
- EVAX N/A
- KZIA N/A
- Revenue Growth
- EVAX N/A
- KZIA 248000.00
- 52 Week Low
- EVAX $2.38
- KZIA $1.35
- 52 Week High
- EVAX $68.05
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- EVAX 23.50
- KZIA 20.80
- Support Level
- EVAX $2.38
- KZIA $1.35
- Resistance Level
- EVAX $3.90
- KZIA $1.89
- Average True Range (ATR)
- EVAX 0.51
- KZIA 0.15
- MACD
- EVAX -0.05
- KZIA 0.05
- Stochastic Oscillator
- EVAX 2.72
- KZIA 3.39
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.